Disease Area Public health

Tracking Zika

| William Aryitey

What do we know so far?

Research Field Neuroscience

When Mice Attack

| William Aryitey

Researchers can control aggression in mice by turning on specific neurons – but what are the implications for human rage?

Research Field Cancer

Fly Eyes Run Amok

| William Aryitey

What can Drosophila eyes tell us about the origins of cancer?

Tools & Techniques Cell & molecular biology

Cellular Night Vision

| William Aryitey

French physicists have developed a thermal imaging technique that maps heat across a single cell

Research Field Cancer

Dendrimer DeLivery

| William Aryitey

How can we get drugs to the liver to treat its dysfunction, without making it worse?

Research Field Neuroscience

Seeds of Alzheimer's

| William Aryitey

Another study supports potential surgical transmission of amyloid beta plaques – but the discussion is far from closed

Disease Area Immunology

Image of the Month

| Charlotte Barker

On each side of the brain stem, a florescent green marker illuminates the two networks of 200 neurons that control the sighing reflex

Outside the Lab Infectious diseases

Video: Inside The Translational Scientist

| Charlotte Barker

Want a lightning-fast tour of the latest issue? Take a look at our new video sneak preview.

Research Field Cardiovascular

State-of-the-Heart Tissue Models

| John Ahrens and Joseph C. Wu

A decade after Shinya Yamanaka brought us induced pluripotent stem cells, our ability to generate an endless supply of human heart cells is being put to good use in research and development.

Research Field Cancer

Unlocking Checkpoint Inhibition

| Eric Rubin, David Matthews

Like many drugs today, pembrolizumab (Keytruda) was the result of a group effort. Here, we catch up with two scientists who shaped the destiny of the biotherapeutic at very different stages in its development.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register